Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte
Stem-Cell Therapy for Type 1 Diabetes Reduced Patient's Insulin Needs by 91%
FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes
DRC's Take: Vertex to Acquire Chief T1D Stem Cell Competitor in All-Cash Deal - Diabetes Research Connection
Vertex to Acquire ViaCyte for $320M, Growing Diabetes Cell Therapy Pipeline
Vertex reports positive results for first patient in Type 1 diabetes trial - The Boston Globe
Vertex Acquires Semma Therapeutics Diabetes Research Firm
Vertex snaps up diabetes stem cell rival | Nature Biotechnology
Vertex stock falls after FDA halts diabetes study in surprise move - The Boston Globe
Vertex präsentiert neue Daten aus der klinischen Phase-1/2-Studie zu VX-880 bei den 82. Scientific Sessions der American Diabetes Association | Business Wire
CRISPR Therapeutics vergibt Lizenz an Vertex - punkt4
Vertex Pharmaceuticals announces they have acquired ViaCyte | JDRF Canada
Vertex: Trial of New Type 1 Diabetes Cell Therapy Put on Hold - DSM
Vertex Expanding into Diabetes Cell Therapy with Plans to Acquire Semma
Vertex Moves Full Steam Ahead on Type 1 Diabetes Drug Trial With FDA's OK | BioSpace
New Vertex Type 1 Stem Cell Therapy Gets FDA Nod to Enter Clinical Trials
Type 1 Diabetes Cures in Spotlight with Vertex Deal
Vertex to acquire rival diabetes drug developer ViaCyte
Vertex Pays CRISPR Therapeutics $100M to Bring Gene-Editing to Type 1 Diabetes - MedCity News
AKTIONÄR-Tipp Vertex: Übernahme – Aktie auf Jahreshoch - DER AKTIONÄR
Vertex buys diabetes cell therapy rival ViaCyte for $320m | pharmaphorum
Vertex signs licence deal with CRISPR for diabetes therapies
Vertex (VRTX) Stock Falls After FDA Pauses Diabetes Study in Surprise Move - Bloomberg
Stem Cell-Based 'Cure' for Type 1 Diabetes
Vertex Releases New Data on Potential Cure for Type 1 Diabetes
Vertex cell therapy lets patients with type 1 diabetes stop insulin
Vertex Pharmaceuticals am 52-Wochenhoch – Studie für Stammzellentherapie gegen Diabetes-Typ-1 wird fortgesetzt!
